-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UMCcYTj1bmP6gdA5ChL/eA1WluPG8zO2l2WcH+iLAvsYaIXUnkeK64GvknGhXvSm
 Tk2ocRGgZtolX0+yeksgYA==

<SEC-DOCUMENT>0000884121-08-000005.txt : 20081126
<SEC-HEADER>0000884121-08-000005.hdr.sgml : 20081126
<ACCEPTANCE-DATETIME>20081126122000
ACCESSION NUMBER:		0000884121-08-000005
CONFORMED SUBMISSION TYPE:	NSAR-B
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20080930
FILED AS OF DATE:		20081126
DATE AS OF CHANGE:		20081126
EFFECTIVENESS DATE:		20081126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			H&Q LIFE SCIENCES INVESTORS
		CENTRAL INDEX KEY:			0000884121
		IRS NUMBER:				043147016
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		NSAR-B
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-06565
		FILM NUMBER:		081216489

	BUSINESS ADDRESS:	
		STREET 1:		2 LIBERTY SQUARE
		STREET 2:		9TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		6175740500

	MAIL ADDRESS:	
		STREET 1:		2 LIBERTY SQUARE
		STREET 2:		9TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
</SEC-HEADER>
<DOCUMENT>
<TYPE>NSAR-B
<SEQUENCE>1
<FILENAME>hqlanswr.fil
<DESCRIPTION>ANSWER FILE
<TEXT>
<PAGE>      PAGE  1
000 B000000 09/30/2008
000 C000000 0000884121
000 D000000 N
000 E000000 NF
000 F000000 Y
000 G000000 N
000 H000000 N
000 I000000 6.1
000 J000000 A
001 A000000 H&Q LIFE SCIENCES INVESTORS
001 B000000 811-6565
001 C000000 6177728500
002 A000000 2 LIBERTY SQUARE 9TH FLOOR
002 B000000 BOSTON
002 C000000 MA
002 D010000 02109
003  000000 N
004  000000 N
005  000000 N
006  000000 N
007 A000000 N
007 B000000  0
007 C010100  1
008 A000001 HAMBRECHT & QUIST CAPITAL MANAGEMENT LLC
008 B000001 A
008 C000001 801-000000
008 D010001 BOSTON
008 D020001 MA
008 D030001 02109
010 A000001 STATE STREET BANK (SUB-ADMINISTRATOR)
010 B000001 85-05003
010 C010001 BOSTON
010 C020001 MA
010 C030001 02111
012 A000001 COMPUTERSHARE TRUST CO. N.A.
012 B000001 85-113400
012 C010001 CANTON
012 C020001 MA
012 C030001 02021
013 A000001 DELOITTE & TOUCHE LLP
013 B010001 BOSTON
013 B020001 MA
013 B030001 02110
015 A000001 STATE STREET BANK & TRUST CO.
015 B000001 C
015 C010001 BOSTON
015 C020001 MA
015 C030001 02110
015 E010001 X
018  000000 Y
019 A000000 N
<PAGE>      PAGE  2
019 B000000    0
020 A000001 PERSHING LLC
020 B000001 13-3769702
020 C000001    122
020 A000002 PIPER JAFFRAY & CO.
020 B000002 41-0953246
020 C000002     69
020 A000003 MERRILL LYNCH & CO.
020 B000003 13-3247006
020 C000003     65
020 A000004 J P MORGAN SECURITIES INC
020 B000004 13-3224013
020 C000004     56
020 A000005 GOLDMAN SACHS & CO.
020 B000005 13-3175029
020 C000005     34
020 A000006 FRIEDMAN BILLINGS & RAMSEY & CO.
020 B000006 52-1630477
020 C000006     33
020 A000007 BANK OF AMERICA CORP.
020 B000007 36-0947896
020 C000007     29
020 A000008 NATIONAL FINANCIAL SERVICES CORP.
020 B000008 04-2785576
020 C000008     27
020 A000009 LEHMAN BROTHERS HOLDINGS, INC.
020 B000009 13-3216325
020 C000009     26
020 A000010 RIDGE CLEARING & OUTSOURCING SOLUTIONS
020 B000010 13-2967453
020 C000010     23
021  000000      624
022 A000001 STATE STREET BANK & TRUST CO.
022 B000001 04-1867445
022 C000001   1542192
022 D000001         0
022 A000002 CITIBANK, N.A.
022 B000002 13-5266470
022 C000002    366635
022 D000002     28530
022 A000003 DEUTSCHE BANK
022 B000003 13-2730828
022 C000003    304256
022 D000003       225
022 A000004 MERRILL LYNCH & CO.
022 B000004 13-3247006
022 C000004     29863
022 D000004         0
022 A000005 ADAMS RESPIRATORY THERAPEUDICS, INC.
022 C000005         0
022 D000005      4989
<PAGE>      PAGE  3
022 A000006 RESPIRONICS, INC.
022 C000006         0
022 D000006      3142
022 A000007 MATRITECH, INC.
022 C000007         0
022 D000007      3129
022 A000008 ELECTRO OPTICAL SCIENCES, INC.
022 C000008      2500
022 D000008         0
022 A000009 SIRTRIS PHARMACEUTICALS, INC.
022 C000009         0
022 D000009      2499
022 A000010 ZIXIT CORP.
022 C000010      2287
022 D000010         0
023 C000000    2252223
023 D000000      44715
024  000000 N
026 A000000 N
026 B000000 Y
026 C000000 N
026 D000000 Y
026 E000000 N
026 F000000 N
026 G010000 N
026 G020000 N
026 H000000 N
027  000000 N
028 A010000         0
028 A020000         0
028 A030000         0
028 A040000         0
028 B010000         0
028 B020000         0
028 B030000         0
028 B040000         0
028 C010000         0
028 C020000         0
028 C030000         0
028 C040000         0
028 D010000         0
028 D020000         0
028 D030000         0
028 D040000         0
028 E010000         0
028 E020000         0
028 E030000         0
028 E040000         0
028 F010000         0
028 F020000         0
028 F030000         0
<PAGE>      PAGE  4
028 F040000         0
028 G010000         0
028 G020000         0
028 G030000         0
028 G040000         0
028 H000000         0
030 A000000      0
030 B000000  0.00
030 C000000  0.00
031 A000000      0
031 B000000      0
032  000000      0
033  000000      0
035  000000      0
036 B000000      0
038  000000      0
042 A000000   0
042 B000000   0
042 C000000   0
042 D000000   0
042 E000000   0
042 F000000   0
042 G000000   0
042 H000000   0
043  000000      0
044  000000      0
045  000000 Y
046  000000 N
047  000000 N
048  000000  0.000
048 A010000        0
048 A020000 0.000
048 B010000        0
048 B020000 0.000
048 C010000        0
048 C020000 0.000
048 D010000        0
048 D020000 0.000
048 E010000        0
048 E020000 0.000
048 F010000        0
048 F020000 0.000
048 G010000        0
048 G020000 0.000
048 H010000        0
048 H020000 0.000
048 I010000        0
048 I020000 0.000
048 J010000        0
048 J020000 0.000
048 K010000        0
<PAGE>      PAGE  5
048 K020000 0.000
049  000000 N
050  000000 N
051  000000 N
052  000000 N
053 A000000 N
054 A000000 Y
054 B000000 N
054 C000000 Y
054 D000000 N
054 E000000 N
054 F000000 N
054 G000000 N
054 H000000 N
054 I000000 N
054 J000000 N
054 K000000 N
054 L000000 N
054 M000000 Y
054 N000000 N
054 O000000 N
055 A000000 Y
055 B000000 N
056  000000 N
057  000000 Y
058 A000000 N
059  000000 Y
060 A000000 Y
060 B000000 Y
061  000000        0
062 A000000 N
062 B000000   0.0
062 C000000   0.0
062 D000000   0.0
062 E000000   0.0
062 F000000   0.0
062 G000000   0.0
062 H000000   0.0
062 I000000   0.0
062 J000000   0.0
062 K000000   0.0
062 L000000   0.0
062 M000000   0.0
062 N000000   0.0
062 O000000   0.0
062 P000000   0.0
062 Q000000   0.0
062 R000000   0.0
063 A000000   0
063 B000000  0.0
066 A000000 Y
<PAGE>      PAGE  6
066 B000000 N
066 C000000 Y
066 D000000 N
066 E000000 N
066 F000000 N
066 G000000 N
067  000000 N
068 A000000 N
068 B000000 N
069  000000 N
070 A010000 Y
070 A020000 Y
070 B010000 Y
070 B020000 Y
070 C010000 N
070 C020000 N
070 D010000 Y
070 D020000 N
070 E010000 N
070 E020000 N
070 F010000 Y
070 F020000 N
070 G010000 Y
070 G020000 N
070 H010000 Y
070 H020000 N
070 I010000 N
070 I020000 N
070 J010000 Y
070 J020000 Y
070 K010000 Y
070 K020000 N
070 L010000 Y
070 L020000 Y
070 M010000 Y
070 M020000 N
070 N010000 Y
070 N020000 N
070 O010000 Y
070 O020000 N
070 P010000 N
070 P020000 N
070 Q010000 N
070 Q020000 N
070 R010000 Y
070 R020000 N
071 A000000    203981
071 B000000    216750
071 C000000    276079
071 D000000   74
072 A000000 12
<PAGE>      PAGE  7
072 B000000      680
072 C000000      987
072 D000000        0
072 E000000        0
072 F000000     3612
072 G000000       77
072 H000000        0
072 I000000       51
072 J000000      101
072 K000000       62
072 L000000       33
072 M000000      191
072 N000000       27
072 O000000        0
072 P000000        0
072 Q000000        0
072 R000000       77
072 S000000      209
072 T000000        0
072 U000000        0
072 V000000        0
072 W000000      144
072 X000000     4584
072 Y000000        0
072 Z000000    -2917
072AA000000    57095
072BB000000    33258
072CC010000        0
072CC020000    39325
072DD010000        0
072DD020000        0
072EE000000    23504
073 A010000   0.0000
073 A020000   0.0000
073 B000000   1.1500
073 C000000   0.0000
074 A000000        0
074 B000000    23712
074 C000000     3495
074 D000000        0
074 E000000    29396
074 F000000   221287
074 G000000        0
074 H000000        0
074 I000000        0
074 J000000     1740
074 K000000        0
074 L000000      113
074 M000000     1246
074 N000000   280989
074 O000000     2657
<PAGE>      PAGE  8
074 P000000      293
074 Q000000        0
074 R010000        0
074 R020000        0
074 R030000        0
074 R040000      219
074 S000000        0
074 T000000   277820
074 U010000    21085
074 U020000        0
074 V010000    13.18
074 V020000     0.00
074 W000000   0.0000
074 X000000        0
074 Y000000        0
075 A000000        0
075 B000000   293720
076  000000    10.62
077 A000000 Y
077 B000000 Y
077 C000000 Y
077 D000000 N
077 E000000 N
077 F000000 N
077 G000000 N
077 H000000 N
077 I000000 N
077 J000000 N
077 K000000 N
077 L000000 N
077 M000000 N
077 N000000 N
077 O000000 N
077 P000000 N
077 Q010000 Y
077 Q020000 N
077 Q030000 N
078  000000 N
080 A000000 MARSH AFFINITY GROUP SERVICES
080 C000000     1500
081 A000000 Y
081 B000000   2
082 A000000 Y
082 B000000       25
083 A000000 N
083 B000000        0
084 A000000 N
084 B000000        0
085 A000000 Y
085 B000000 N
086 A010000   1002
<PAGE>      PAGE  9
086 A020000  11733
086 B010000      0
086 B020000      0
086 C010000      0
086 C020000      0
086 D010000      0
086 D020000      0
086 E010000      0
086 E020000      0
086 F010000      0
086 F020000      0
087 A010000 H&Q LIFE SCIENCES INVESTORS
087 A020000 404053100
087 A030000 HQL
088 A000000 N
088 B000000 N
088 C000000 N
088 D000000 N
SIGNATURE   CAROLYN HALEY
TITLE       CHIEF COMPLIANCE OF.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.77B ACCT LTTR
<SEQUENCE>2
<FILENAME>hqlaltr.txt
<DESCRIPTION>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
Report of Independent Registered Public Accounting Firm
To the Trustees and Shareholders of H and Q Life Science Investors:

In planning and performing our audit of the financial statements of
H and Q Life Science Investors (the Fund) as of and for the year ended
September 30, 2008, in accordance with the Standards of the Public
Company Accounting Oversight Board (United States), we considered its
internal control over financial reporting, including control activities
for safeguarding securities, as a basis for designing our auditing
procedures for the purpose of expressing our opinion on the financial
statements and to comply with the requirements of Form N-SAR, but not
for the purpose of expressing an opinion on the effectiveness of the
Funds internal control over financial reporting.  Accordingly, we
express no such opinion.

Management of the Fund is responsible for establishing and maintaining
effective internal control over financial reporting.  In fulfilling
this responsibility, estimates and judgments by management are required
to assess the expected benefits and related costs of controls.  The
Funds internal control over financial reporting is a process designed
to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with accounting principles generally accepted in
the United States of America (generally accepted accounting
principles).  Such internal control includes policies and procedures
that provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use or disposition of a Funds
assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements.  Also, projections
of any evaluation of effectiveness to future periods are subject to the
risk that controls may become inadequate because of changes in
conditions, or that the degree of compliance with the policies or
procedures may deteriorate.

A control deficiency exists when the design or operation of a control
does not allow management or employees, in the normal course of
performing their assigned functions, to prevent or detect misstatements
on a timely basis.  A significant deficiency is a control deficiency,
or combination of control deficiencies, that adversely affect the
Funds ability to initiate, authorize, record, process or report
financial data reliably in accordance with generally accepted
accounting principles such that there is more than a remote likelihood
that a misstatement of the Funds annual or interim financial
statements that is more than inconsequential will not be prevented or
detected.  A material weakness is a significant deficiency, or
combination of significant deficiencies, that results in more than a
remote likelihood that a material misstatement of the annual or interim
financial statements will not be prevented or detected.

Our consideration of the Funds internal control over financial
reporting was for the limited purpose described in the first paragraph
and would not necessarily disclose all deficiencies in internal control
that might be significant deficiencies or material weaknesses under
standards established by the Public Company Accounting Oversight Board
(United States).  However, we noted no deficiencies in the Funds
internal controls over financial reporting and its operation, including
controls for safeguarding securities that we consider to be a material
weakness, as defined above, as of September 30, 2008.

This report is intended solely for the information and use of
management, the Board of Trustees and Shareholders of H and Q Life Science
Investors, and the Securities and Exchange Commission and is not
intended to be and should not be used by anyone other than these
specified parties.

DELOITTE and TOUCHE LLP

Boston, Massachusetts
November 20, 2008
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.77C VOTES
<SEQUENCE>3
<FILENAME>hqlamr.txt
<DESCRIPTION>ANNUAL MEETING REPORT
<TEXT>
ANNUAL MEETING REPORT

   An Annual Meeting of Shareholders was held on June 12, 2008.
Shareholders voted to elect three Trustees of the Fund to hold office
for a term of three years or until their respective successors shall
have been duly elected and qualified. The following votes were cast
with respect to each of the nominees.

                      For          Withheld
Rober P. Mack, M.D.   16,695,672   1,370,985
Eric Oddleifson       16,824,029   1,242,648
Oleg Pohotsky         16,683,030   1,383,647

   The nominees were elected to serve until the 2011 Annual Meeting.
Trustees serving until the 2009 Annual Meeting are Rakesh K. Jain,
Ph.D., Daniel R. Omstead, Ph.D. and Lucinda H. Stebbins. Trustees
serving until the 2010 Annual Meeting are Lawrence S. Lewin and Uwe E.
Reinhardt, Ph.D.

   Shareholders ratified the appointment of Deloitte & Touche LLP as
the independent registered public accountants of the Fund for the
fiscal year ending September 30, 2008 by the following votes.

For          Against   Abstain
17,669,021   198,608   199,048
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.77C VOTES
<SEQUENCE>4
<FILENAME>hqlshp.txt
<DESCRIPTION>SHAREHOLDER PROPOSALS
<TEXT>
SHAREHOLDER PROPOSALS

   On July 17, 2008, the Board of Trustees amended the by-laws of the
Fund. The Trustees determined that the by-laws should be updated in
order to ensure an orderly and informed shareholder meeting process for
all participating shareholders. Generally, the amendments:
(i) provide that holders of a majority of shares of the Fund entitled
to vote at a meeting may call a special meeting of shareholders, (ii)
further specify the process for calling such a meeting, and (iii)
establish time periods and information requirements for calling a
special meeting and for the submission of shareholder proposals (other
than pursuant to regulations of the U.S. Securities and Exchange
Commission (SEC)). These amendments do not affect the notice period for
each shareholder proposal submitted for inclusion in the Funds proxy
statements pursuant to the SECs rules. With respect to other
nominations or proposals, for each annual meeting of shareholders, the
amended by-laws require that the Fund receive notice of the nomination
or proposal and certain additional information at least 90 days but no
more than 120 days in advance of the first anniversary of the previous
years annual meeting. For each special meeting of shareholders, the
amended by-laws require that the Fund receive notice of a nomination or
proposal within 10 business days after the meeting is publicly
announced, including by press release, a filing with the SEC, or a
posting on the Advisers website. The amended by-laws have been filed
as an exhibit to the Funds registration statement on Form N-2. The
Funds Form N-2 is available at the SECs website at www.sec.gov.
   Shareholder proposals for the Funds 2009 annual meeting of
shareholders must be received at the Funds executive offices (2
Liberty Square, 9th Floor, Boston, Massachusetts 02109) no later than
January 8, 2009, in order to be included in the Funds proxy statement
and form of proxy. Other shareholder nominations or proposals for the
Funds 2009 annual meeting must be received at the Funds executive
offices between February 12, 2009, and March 14, 2009. Submission of
such proposals does not ensure that they will be included in the proxy
statement or submitted for a vote at the 2009 annual meeting.

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
